We previously established a highly metastatic subline, LNM35, from the NCI-H460 lung cancer cell line, and demonstrated upregulation of a novel gene, CLCP1 (CUB, LCCL-homology, coagulation factor V/VIII homology domains protein), in LNM35 and lung cancer specimens. In this study, we focused on the potential roles of that gene in cancer metastasis. First, we established stable LNM35 RNAi clones, in which CLCP1 expression was suppressed by RNAi, and found that their motility was significantly reduced, although growth rates were not changed. Next, in vitro selection of a phage display library demonstrated that a phage clone displaying a peptide similar to a sequence within the Sema domain of semaphorin 4B (SEMA4B) interacted with LNM35. Immunoprecipitation experiments confirmed interaction of CLCP1 with SEMA4B, regulation of CLCP1 protein by ubiquitination and proteasome degradation enhanced in the presence of SEMA4B. These results are the first to indicate that CLCP1 plays a role in cell motility, whereas they also showed that at least one of its ligands is SEMA4B and that their interaction mediates proteasome degradation by CLCP1. Although the physiological role of the interaction between CLCP1 and SEMA4B remains to be investigated, this novel gene may become a target of therapy to inhibit metastasis of lung cancers.
Lung cancer is the leading cause of cancer-related death in developed countries. Despite a considerable body of knowledge regarding the molecular mechanisms of development and progression of lung cancer, most patients eventually die because of widespread metastases. Thus, it is considered important to identify the molecules that play crucial roles in cell motility/invasion and metastasis in order to significantly reduce mortality rates. For this purpose, we established a highly metastatic subline, LNM35, from the NCI-H460 human lung cancer cell line (Kozaki et al., 2000) , which showed upregulation of various proinflammatory cytokines and angiogenic chemotactic chemokines in comparison to a representative low metastatic clone of the parental line (Kozaki et al., 2001) . Based on this profiling analysis, we also identified and characterized a novel gene, CLCP1 (CUB, LCCL-homology, coagulation factor V/VIII homology domains protein), also termed endothelial and smooth muscle cell-derived neuropilin-like molecule (ESDN)/discoidin, CUB and LCCL domain containing 2 (DCBLD2) (Kobuke et al., 2001) , that demonstrated upregulated expression in LNM35 as well as in a significant fraction of lung cancers, especially lymph node metastases (Koshikawa et al., 2002) . The CLCP1 gene encodes a 775-amino-acid protein with structural similarities to neuropilins, cell surface receptors for vascular endothelial growth factor (VEGF) 165 and semaphorins (Koshikawa et al., 2002) , which were originally identified as neural axon repulsion signaling molecules active in axon guidance. Some class III semaphorins function as tumor suppressors, whereas one class IV member may promote tumor progression through induction of angiogenesis (Kruger et al., 2005) . In the present study, we explored the functions of CLCP1 in tumor progression and metastasis, and found that knock down reduces tumor cell motility. Using the phage peptide library, we also obtained evidence that at least one ligand of CLCP1, Sema domain of the human semaphorin 4B (SEMA4B), is a class IV semaphorin that may be also involved in the regulation of cell motility through its induction of CLCP1 degradation.
Observation of a high expression of CLCP1 in lung cancer specimens prompted us to examine its functional contribution to the high metastatic properties of LNM35 cells. We generated several small interfering RNA (siRNA) constructs expressing short hairpin RNAs targeting CLCP1, and found two siRNA sites (siCLCP1-2 and siCLCP1-3) that were able to effectively knock down CLCP1 expression in 293T cells co-transfected with a CLCP1 expression vector and an siRNA vector (Figure 1a ). To determine whether these findings were associated with decreased cell growth and/ or motility of LNM35, we established stable LNM35 transfectant clones. Northern blotting (Figure 1b ) revealed that the expression level of CLCP1 in siCLCP1-3 clones nos. 3, 9 and 42 was significantly reduced to the level of the parental subclone of NCI-H460, N15, whereas CLCP1 expression was not affected in control siGreen fluorescent protein (siGFP) clones (Supplementary Figure 3 ). Thereafter, these three siCLCP1-3 clones were employed for further biological analyses.
Cell growth rate was studied and the growth rates of the siCLCP1-3 clones were quite similar to those of siGFP clones (Figure 2a ), suggesting that CLCP1 expression is not involved in the regulation of cell growth in LNM35 cells. However, motility was significantly decreased in the siCLCP1-3 clones, whereas the siGFP clones retained high motility (Figure 2b and c), implying that CLCP1 has an effect to enhance cell migration.
Concurrently with the above analyses, we searched for cell surface molecules specific to LNM35 using a phage display method in order to identify the molecular mechanisms of the high motility/invasion ability of LNM35. One of the peptides enriched with this method was SAYIPDS, whose sequence was nearly identical to that of SAYIPES within the SEMA4B gene (Figure 3a) . This domain is known to be crucial for interactions with other proteins. CLCP1 has structural similarities to neuropilins, which function as cell surface receptors for semaphorins, therefore, we speculated that the selected peptide and SEMA4B might interact with CLCP1. We compared the interactions of the phage with LNM35 (high CLCP1 expression) and N15 (low CLCP1 expression). When cells were incubated with the phage displaying the (Koshikawa et al., 2002) . A control RNAi construct for the GFP gene, siGFP, was also used. Note the significant reduction of expression of CLCP1 protein observed with siCLCP1-2 and siCLCP1-3. (b) Northern blotting of stable LNM35-RNAi clones. LNM35 was transfected with siCLCP1-3 RNAi constructs and selected with neomycin (1 mg/ml) for 2 weeks. The expression of endogenous CLCP1 transcripts was almost undetectable in the LNM35 siCLCP1-3 clones (nos. 3, 9 and 42), whereas the high level of expression of CLCP1 was not affected in control clones that received the siGFP construct. Note the significant difference in CLCP1 expression level between LNM35 and the parental line N15. 4 per dish in RPMI1640 medium with 5% fetal bovine serum and neomycin, then cell numbers were counted each day with a Z1 Coulter Counter (Beckman Coulter, Fullerton, CA, USA). The growth rates of the siCLCP1-3 clones were quite similar to those of the control siGFP clones, (b, c) in vitro motility assay. Motility of the RNAi clones was studied using transwell chambers, as described previously (Kozaki et al., 2001 ) and found to be significantly decreased in all three siCLCP1-3 clones (white bars), whereas the siGFP clones (hatched bars) retained their high levels of motility. (c) A number of migrated cells were observed among the LNM35 cells by Giemsa staining, whereas there were very few N15 or siCLCP1 cells ( Â 40 magnification). The small dots represent 8 mm-sized transwell chamber pores.
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H Nagai et al Figure 3 CLCP1 interacts with SEMA4B. (a) In vitro selection of LNM35 cells using a phage display library (PhD-7 Phage Display Peptide Library, New England Biolabs, Ipswich, MA, USA). For each selection, 1-2 Â 10 11 PFU of phage particles were overlaid on LNM35 cells. After incubation and washing, attached phages were eluted with acid elution buffer (acid-associated fraction (AAF)). Tightly associated phages were also recovered after cell lysis (cell-associated fraction (CAF)). The phages were amplified following infection with bacteria and rounds of incubation-elution-amplification were repeated. Seven of the eight AAF phage clones sequenced after four rounds of selection contained the SAYIPDS peptide, which was nearly identical to the sequence SAYIPES within the SEMA4B gene. CAF phage results indicated the sequence of a hypothetical protein FLJ12634. (b) Immunofluorescence of phages attached to LNM35. Both LNM35 (with high CLCP1 expression) and N15 (with low CLCP1 expression) cells were incubated with phages displaying the SAYIPDS peptide. After washing and fixation, cell-attached phages were immuno-stained with the monoclonal antibody against M13 procoat protein (GE Healthcare Bio-Science, Piscataway, NJ, USA) and Alexa488-conjugated anti-mouse IgG (Invitrogen, Carlsbad, CA, USA). Note the stronger binding of the SAYIPDS phage with LNM35 as compared to that with N15. (c, d) Co-immunoprecipitation of CLCP1 with SEMA4B. The SEMA4B cDNA clone, KIAA1745, was kindly provided by Kazusa DNA Research Institute. For the SEMA4B-myc expression construct, the SEMA4B ORF was introduced into pcDNA3 (Invitrogen) together with myc-tag at its C-terminus. For the SEMA4B-Fc-myc construct, a 1720-bp SacII-BamHI fragment of KIAA1745 containing only the Sema domain was fused to the cDNA of the human IgG1 Fc portion in the pcDNA vector with an myc-tag at the C-terminus of the Fc portion. SEMA4B-myc or SEMA4B-Fc-myc was co-transfected with CLCP1-HA into 293T cells, and the generated proteins were immunoprecipitated with mouse monoclonal anti-myc-tag antibody 9E10. Immunoblots of these precipitates with rabbit anti-HA antibodies clearly demonstrated co-immunoprecipitation of CLCP1 with SEMA4B proteins. (e) Immunofluorescence of SEMA4B and CLCP1. The A549 lung cancer cell line was transfected with SEMA4B-myc and CLCP1-HA expression vectors, then stained with Alexa Fluor dye-labeled secondary antibodies (Invitrogen) after MG-132 treatment, as performed in Figure  4b and c. Observation with a confocal microscope (Olympus, Tokyo, Japan) showed both CLCP1 and SEMA4B to be mainly localized on the cell surface membrane, with colocalization clearly observed in merged images.
CLCP1 regulates lung cancer cell motility with SEMA4B H Nagai et al SAYIPDS peptide and then immuno-stained with the anti-M13 antibody against the phage particle, LNM35 staining was more intense than that of N15 (Figure 3b) . Next, the indicated interaction between CLCP1 and SEMA4B was studied using an myc-tagged full-length SEMA4B construct, as well as an myc-tagged SEMA4B-Fc fusion construct consisting of the SEMA4B Sema domain and immunoglobulin (Ig)G Fc portion. After co-transfection with hemagglutinin (HA)-CLCP1 into 293T cells, anti-HA immunoblotting of anti-myc immunoprecipitates clearly demonstrated co-precipitation of CLCP1 with SEMA4B or SEMA4B-Fc (Figure 3d) . Further, colocalization of CLCP1 and SEMA4B proteins on cell surface membranes was demonstrated by immunofluorescence analysis (Figure 3e) .
HA-tagged CLCP1 demonstrated two sizes, 130 and 110 kDa, which were both larger than the predicted molecular mass of 80 kDa. We previously speculated that post-translational modifications such as glycosylation might account for this discrepancy (Koshikawa et al., 2002) , as is the case with most transmembrane proteins. To confirm this, 293T cells were transfected with HA-CLCP1 and then treated with tunicamycin, which blocks the first step in the biosynthesis of Nlinked oligosaccharides. Tunicamycin treatment reduced the amounts of both the 130-and 110-kDa bands in a dose-dependent manner. Simultaneously, a novel 80-kDa band appeared (Figure 4a ), indicating that CLCP1 protein is indeed post-translationally modified by glycosylation, resulting in 130-and 110-kDa-sized proteins, which might be properly processed into transmembrane proteins.
We found that the intensity of the CLCP1 protein band was significantly weaker after CLCP1-SEMA4B co-transfection as compared to with CLCP1 transfection alone (Figure 4b) , and subsequently attempted to determine whether SEMA4B caused degradation of CLCP1 protein in a proteasome-dependent manner. When 293T cells were transfected with CLCP1 and/ or SEMA4B, and then treated with MG-132, a specific inhibitor of proteasomes, anti-HA immunoblots indicated an increased intensity of both the 130-and 110-kDa bands in the CLCP1 transfectants (Figure 4b , lanes 3 and 4), suggesting that CLCP1 alone was originally regulated by proteasome degradation. However, CLCP1-SEMA4B and CLCP1-SEMA4B-Fc cotransfection were both associated with a significantly reduced intensity of the largest band (130 kDa) (Figure 4b, lanes 5 and 7) . Similarly, MG-132 treatment enhanced the intensity of the 110-kDa band (Figure 4b , lanes 4, 6 and 8). However, the 130-kDa band was only moderately restored with CLCP1-SEMA4B co-transfection (Figure 4b, lane 6) and not recovered at all with CLCP1-SEMA4B-Fc co-transfection (Figure 4b , lane 8). In Figure 4c , the size of the co-immunoprecipitated CLCP1 isoform was compared with that of CLCP1 proteins in cell lysates derived from transfectants treated with or without MG-132 or another proteasome inhibitor, lactacystin, which was effective for a Smad4 mutant (Yanagisawa et al., 2000) ( Supplementary  Figures 1 and 2) . The main co-precipitated CLCP1 isoform appeared to be a 110-kDa isoform, even in samples treated with proteasome inhibitors. These findings suggest that the degradation of the 130-kDa band induced by SEMA4B proteins may be too severe to be inhibited by the applied concentration of MG-132. Nevertheless, even with higher concentrations of proteasome inhibitors, full restoration of the 130-kDa band was not obtained (Supplementary Figure 2) , suggesting that the interactions with SEMA4B proteins, especially SEMA4B-Fc, may not only induce degradation, but also affect full glycosylation of CLCP1. We also examined the ubiquitination status of CLCP1 using P4D1 monoclonal antibodies that recognize both monoUb and polyUb (Figure 4d ). Although ubiquitinated CLCP1 was readily detected in cells co-transfected with the empty vector (Figure 4d, lane 4) , the ubiquitination of CLCP1 was significantly increased following co-transfection with SEMA4B ( Figure 4d , lane 6). These results suggest that CLCP1-SEMA4B interactions induce significant degradation of CLCP1 proteins, especially 130-kDa fully-glycosylated CLCP1.
This present results indicated that the neuropilin-like protein CLCP1 is upregulated in highly metastatic lung cancer cells and may promote cell motility, possibly resulting in promotion of metastasis. We also found that SEMA4B is a possible ligand of CLCP1, as CLCP1-SEMA4B interaction caused CLCP1 degradation. CLCP1/ESDN was also reported to be expressed by vascular smooth muscle cells, as well as upregulated by platelet-derived growth factor-BB stimulation and vascular injury, suggesting that it modulates growthpromoting signals (Kobuke et al., 2001) . Class III semaphorins interact with neuropilins through binding of their Sema and CUB or FV/VIII domains, respectively. Although the interaction domains of CLCP1 and SEMA4B have yet to be determined, it is conceivable that the Sema domain of SEMA4B interacts with CUB and FV/VIII domains of CLCP1. The fact that the sequence within the Sema domain was enriched with the phage display selection in LNM35 expressing CLCP1 provides support for this speculation.
Cell migration is a multistep process that includes leading edge protrusion, focal contact formation and actomyosin-dependent cell contraction, and also involves small guanosine triphosphatase (GTPase) and integrins. Small GTPases, including Rho, Rac and Cdc42, control cell motility by regulating actin and microtubule dynamics (Friedl and Wolf, 2003) . Semaphorins and neuropilins make protein complexes with plexins, which regulate the activities of small GTPases through interactions with these small GTPases and Rhoguanine nucleotide exchange factor (Kruger et al., 2005) . In addition, a recent report showed that Sema4D-plexin-B1 interaction downregulates R-Ras activity through the endogenous GTPase-activating protein activity of plexin-B1, resulting in inhibition of focal contact mediated by integrins (Oinuma et al., 2004) . Therefore, to understand the molecular mechanisms underlying the regulation of cell motility by CLCP1, it is important to clarify whether CLCP1 signaling has any effects on the activities of these small GTPases and integrins.
In a previous study, SEMA3A inhibited the migration and spread of a breast cancer cell line, MDA-MB-231, which expresses neuropilin-1 and plexin-A1, whereas another ligand of neuropilin-1, VEGF 165 , was shown to compete with SEMA3A and abrogate its inhibitory effect (Bachelder et al., 2003) . CLCP1 may also interact with other ligand molecules, which might regulate cell motility in competition with SEMA4B. In the present study, we also examined the involvement of cyclooxygenase 2 (COX-2) in CLCP1 expression (Supplementary  Figure 4) , because a previous study showed that COX-2 was upregulated in LNM35 cells and contributed to their highly metastatic characteristics (Kozaki et al., 2000) . We found that nimesulide, a COX-2 inhibitor, repressed CLCP1 mRNA levels, suggesting a functional association between COX-2 activation and CLCP1 overexpression in LNM35 cells.
SEMA3B and SEMA3F, which are localized at the 3p21.3 locus, are frequently deleted in lung cancers and have been found to suppress tumor cell proliferation Xiang et al., 2002; Castro-Rivera et al., 2004) . In contrast, class IV semaphorins do not show 293T cells were transfected with CLCP1-HA, SEMA4B-myc and/or SEMA4B-Fc-myc, then treated with a proteasome inhibitor, MG-132 (SIGMA-ALDRICH, St Louis, MO, USA), at 10 mM for 24 h. The expression levels of CLCP1 and SEMA4B proteins were then investigated using anti-HA and anti-myc antibodies. Without MG-132 treatment, the CLCP1 protein band was significantly weaker after CLCP1/SEMA4B or CLCP1/SEMA4B-Fc co-transfection (lanes 5, 7) than with CLCP1 transfection alone (lane 3). MG-132 treatment enhanced the intensity of the CLCP1 protein band in co-transfections (lanes 6, 8) and also with CLCP1 transfection alone (lane 4). Proteasome-dependent degradations of SEMA4B proteins were also observed. (c) Analysis of the coimmunoprecipitated isoform of CLCP1. Immunoprecipitation and immunoblotting of CLCP1/SEMA4B and CLCP1/SEMA4B-Fc co-transfected cells were conducted, the same as in Figure 3d . Transfected cells were treated with MG-132 (10 mM) or another proteasome inhibitor, lactacystin (15 mM, Wako Pure Chemical Industries Ltd.). Immunoprecipitated proteins (lane 1, 2) were run with cell lysates before immunoprecipitation (lane 3, 4). The main immunoprecipitated CLCP1 isoform appeared to be the same 110-kDa isoform noted in (a). (d) Ubiquitination of CLCP1. As in (b), 293T cells were transfected and treated with MG-132. Then, CLCP1 protein was immunoprecipitated with the anti-HA antibody and analysed with the anti-ubiquitin antibody, P4D1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Ubiquitination of CLCP1 was readily detected following transfection of CLCP1 alone (lane 4) and significantly increased by co-transfection with SEMA4B (lane 6).
CLCP1 regulates lung cancer cell motility with SEMA4B H Nagai et al such a tumor suppressor function, whereas Sema4D was originally reported to promote B-cell survival and T-cell activation. Another study showed that Sema4D induces angiogenesis, which was mediated by the coupling of its high-affinity receptor plexin-B1 with the Met tyrosine kinase (Conrotto et al., 2005) . In addition, class IV semaphorins frequently have PDZ {PSD (postsynaptic density protein) 95, DlgA (Discs large A), and ZO (zonula occludens) 1)} domain-binding motifs at their C-termini, through which they may function as receptors by mediating signal transfers through their intracellular domains. SEMA4B, 4C and 4F have been shown to interact with the PDZ domains of PSD-95 (Inagaki et al., 2001; Burkhardt et al., 2005) , whereas SEMA4D was found to associate with CD45 protein tyrosine phosphatase (Herold et al., 1996) . Therefore, SEMA4B might function as a CLCP1 receptor. Sema3A-neuropilin interactions induce neuropilin-1 endocytosis, which is mediated by L1-CAM (Fournier et al., 2000; Castellani et al., 2004) , which in turn modulates growth cone sensitivity to semaphorin repulsion signals. CLCP1 degradation after CLCP1-SEMA4B interaction may indicate an induction of CLCP1 endocytosis by SEMA4B.
In conclusion, the present results indicate that CLCP1 and its interactions with ligands including SEMA4B may become molecular targets for therapeutic inhibition of metastasis. In addition to CLCP1-siRNA, the suppression of CLCP1 functions with dominant-negative CLCP1 or negatively regulating ligands might inhibit in vitro motility and, consequently, in vivo metastasis of cancer cells. Fine mapping of the interacting regions between CLCP1 and SEMA4B may indicate concrete molecular targets. Although a full understanding of the biological roles of CLCP1 and SEMA4B remains to be achieved, further investigations of CLCP1 functions should provide novel and useful strategies to improve the clinical prognosis of lung cancer patients by facilitating the suppression of metastasis.
